METTL3 and colorectal carcinoma: In addition to the malignant characteristics of CRC, METTL3 can also regulate chemotherapeutic resistance by processing miR-181d-5p via DiGeorge Syndrome Critical Region 8 (DGCR8) (Pan et al., 2022).